These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27884597)

  • 1. Prediction of Competing Mortality for Decision-making Between Surgery or Observation in Elderly Patients With T1 Kidney Cancer.
    Larcher A; Trudeau V; Dell'Oglio P; Tian Z; Boehm K; Fossati N; Capitanio U; Briganti A; Montorsi F; Karakiewicz P
    Urology; 2017 Apr; 102():130-137. PubMed ID: 27884597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A non-cancer-related survival benefit is associated with partial nephrectomy.
    Sun M; Trinh QD; Bianchi M; Hansen J; Hanna N; Abdollah F; Shariat SF; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI
    Eur Urol; 2012 Apr; 61(4):725-31. PubMed ID: 22172373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years.
    Marchioni M; Preisser F; Bandini M; Nazzani S; Tian Z; Kapoor A; Cindolo L; Abdollah F; Tilki D; Briganti A; Montorsi F; Shariat SF; Schips L; Karakiewicz PI
    Eur Urol Focus; 2019 May; 5(3):467-473. PubMed ID: 29398456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database.
    Lughezzani G; Sun M; Perrotte P; Shariat SF; Jeldres C; Budäus L; Latour M; Widmer H; Duclos A; Bénard F; McCormack M; Montorsi F; Karakiewicz PI
    Urology; 2010 Feb; 75(2):321-7. PubMed ID: 19962727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-based assessment of cancer-specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis.
    Larcher A; Trudeau V; Sun M; Boehm K; Meskawi M; Tian Z; Fossati N; Dell'Oglio P; Capitanio U; Briganti A; Shariat SF; Montorsi F; Karakiewicz PI
    BJU Int; 2016 Oct; 118(4):541-6. PubMed ID: 26384713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management.
    Sun M; Becker A; Tian Z; Roghmann F; Abdollah F; Larouche A; Karakiewicz PI; Trinh QD
    Eur Urol; 2014 Jan; 65(1):235-41. PubMed ID: 23567066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma.
    Crépel M; Jeldres C; Sun M; Lughezzani G; Isbarn H; Alasker A; Capitanio U; Shariat SF; Arjane P; Widmer H; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
    Urology; 2010 Oct; 76(4):883-8. PubMed ID: 20932408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma.
    Trudeau V; Larcher A; Sun M; Boehm K; Dell'Oglio P; Sosa J; Tian Z; Fossati N; Briganti A; Shariat SF; Karakiewicz PI
    World J Urol; 2016 Oct; 34(10):1429-36. PubMed ID: 26902877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis.
    Psutka SP; Gulati R; Jewett MAS; Fadaak K; Finelli A; Legere L; Morgan TM; Pierorazio PM; Allaf ME; Herrin J; Lohse CM; Houston Thompson R; Boorjian SA; Atwell TD; Schmit GD; Costello BA; Shah ND; Leibovich BC
    Eur Urol; 2022 Jun; 81(6):576-585. PubMed ID: 34862099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-specific Mortality in T1a Renal Cell Carcinoma Treated with Local Tumor Destruction Versus Partial Nephrectomy.
    Sorce G; Hoeh B; Hohenhorst L; Panunzio A; Tappero S; Tian Z; Kokorovic A; Larcher A; Capitanio U; Tilki D; Terrone C; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
    Eur Urol Focus; 2023 Jan; 9(1):125-132. PubMed ID: 35918270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.
    Moltzahn F; Karnes J; Gontero P; Kneitz B; Tombal B; Bader P; Briganti A; Montorsi F; Van Poppel H; Joniau S; Spahn M
    Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):31-7. PubMed ID: 25535100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.
    Bianchi M; Gandaglia G; Trinh QD; Hansen J; Becker A; Abdollah F; Tian Z; Lughezzani G; Roghmann F; Briganti A; Montorsi F; Karakiewicz PI; Sun M
    Urol Oncol; 2014 Jan; 32(1):46.e1-7. PubMed ID: 24054864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma.
    Palumbo C; Cyr SJ; Mazzone E; Mistretta FA; Knipper S; Pecoraro A; Tian Z; Shariat SF; Saad F; Simeone C; Briganti A; Kapoor A; Antonelli A; Karakiewicz PI
    J Endourol; 2019 Jul; 33(7):606-613. PubMed ID: 30990074
    [No Abstract]   [Full Text] [Related]  

  • 14. Results of a comparative study analyzing octogenarians with renal cell carcinoma in a competing risk analysis with patients in the seventh decade of life.
    May M; Cindolo L; Zigeuner R; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Wolff I; Feciche B; Fenske F; Pichler M; Schips L; Figenshau RS; Madison K; Sánchez-Chapado M; Santiago Martin Mdel C; Salzano L; Lotrecchiano G; Waidelich R; Stief C; Sountoulides P; Brookman-May S; ;
    Urol Oncol; 2014 Nov; 32(8):1252-8. PubMed ID: 25129141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities.
    Sun M; Bianchi M; Trinh QD; Hansen J; Abdollah F; Hanna N; Tian Z; Shariat SF; Montorsi F; Perrotte P; Karakiewicz PI
    BJU Int; 2013 Jan; 111(1):67-73. PubMed ID: 22612472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma.
    Palumbo C; Mistretta FA; Knipper S; Mazzone E; Pecoraro A; Tian Z; Perrotte P; Antonelli A; Montorsi F; Shariat SF; Saad F; Simeone C; Briganti A; Lavallee LT; Karakiewicz PI
    Minerva Urol Nefrol; 2020 Jun; 72(3):350-359. PubMed ID: 31487976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.
    Abdollah F; Sun M; Schmitges J; Tian Z; Jeldres C; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
    Eur Urol; 2011 Nov; 60(5):920-30. PubMed ID: 21741762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
    Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
    Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first competing risk survival nomogram in patients with papillary renal cell carcinoma.
    Su X; Hou NN; Yang LJ; Li PX; Yang XJ; Hou GD; Gao XL; Ma SJ; Guo F; Zhang R; Zhang WH; Qin WJ; Wang FL
    Sci Rep; 2021 Jun; 11(1):11835. PubMed ID: 34088935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.